COVID-19 and Fungal infections: a double debacle.
Microbes Infect
; 24(8): 105039, 2022.
Article
in English
| MEDLINE | ID: covidwho-2272233
ABSTRACT
Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients Aspergillus, Candida, and Mucorales species.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Coinfection
/
COVID-19
/
Mycoses
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Microbes Infect
Journal subject:
Allergy and Immunology
/
Microbiology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS